GT200300014A - Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 - Google Patents
Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1Info
- Publication number
- GT200300014A GT200300014A GT200300014A GT200300014A GT200300014A GT 200300014 A GT200300014 A GT 200300014A GT 200300014 A GT200300014 A GT 200300014A GT 200300014 A GT200300014 A GT 200300014A GT 200300014 A GT200300014 A GT 200300014A
- Authority
- GT
- Guatemala
- Prior art keywords
- orl
- ligands
- receiver
- compounds
- spiropiperidine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE ESPIROPIPERIDINA SUSTITUIDOS DE FORMULA GENERAL I EN DONDE DE R1 A R15, X1,X2, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON LIGANDOS PARA EL RECEPTOR ORL1 SIENDO ANTAGONISTAS SELECTIVOS POR LO QUE SON DE UTILIDAD EN UNA AMPLIA VARIEDAD DE PATOLOGIAS TALES COMO TRASTORNOS ALIMENTARIOS, DE ANSIEDAD, LOCOMOTORES ENTRE OTROS DESCRITOS EN LA SOLICITUD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35243702P | 2002-01-28 | 2002-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200300014A true GT200300014A (es) | 2003-08-22 |
Family
ID=27663095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200300014A GT200300014A (es) | 2002-01-28 | 2003-01-24 | Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 |
Country Status (13)
Country | Link |
---|---|
US (1) | US6869960B2 (es) |
EP (1) | EP1470126A1 (es) |
JP (1) | JP2005519921A (es) |
AR (1) | AR038235A1 (es) |
BR (1) | BR0307268A (es) |
CA (1) | CA2466915A1 (es) |
GT (1) | GT200300014A (es) |
MX (1) | MXPA04007242A (es) |
PA (1) | PA8564201A1 (es) |
PE (1) | PE20030848A1 (es) |
TW (1) | TW200302725A (es) |
UY (1) | UY27623A1 (es) |
WO (1) | WO2003064425A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6374762B1 (en) * | 1997-10-27 | 2002-04-23 | Correct Craft, Inc. | Water sport towing apparatus |
EP1601674B1 (en) | 2002-09-09 | 2012-08-08 | Janssen Pharmaceutica NV | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
ITMI20031349A1 (it) * | 2003-07-01 | 2005-01-02 | Ufpeptides S R L | Antagonisti del recettore nop e loro usi terapeutici. |
WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
JPWO2005085228A1 (ja) * | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | シクロアルカノピリジン誘導体 |
EP1732928A2 (en) | 2004-03-29 | 2006-12-20 | Pfizer, Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
WO2005117862A1 (en) * | 2004-06-03 | 2005-12-15 | Pfizer Limited, | Treatment of urinary conditions including incontinence |
US7786141B2 (en) * | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
JP2008510728A (ja) * | 2004-08-19 | 2008-04-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
US7863449B2 (en) | 2004-11-29 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY158766A (en) | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
JP2008542375A (ja) * | 2005-06-02 | 2008-11-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Orl−1受容体モジュレーターとして有用な新規3−スピロ環式インドリル誘導体 |
US20080200490A1 (en) * | 2005-06-17 | 2008-08-21 | Pfizer Inc. | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists |
KR20080087841A (ko) * | 2005-12-22 | 2008-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린 수용체의 조절제 |
CA2643320A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
JP2009527569A (ja) | 2006-02-22 | 2009-07-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体の調節剤 |
GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
EP2040706A2 (en) * | 2006-06-29 | 2009-04-01 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
WO2008021375A2 (en) * | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
US7786107B2 (en) * | 2006-08-18 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2008060789A2 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
EP2102206B1 (en) * | 2006-11-28 | 2015-04-08 | Janssen Pharmaceutica NV | Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
EP2150552B1 (en) | 2007-04-09 | 2013-01-02 | Janssen Pharmaceutica NV | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
US7973162B2 (en) * | 2007-10-03 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
RU2015103694A (ru) | 2009-10-14 | 2015-06-27 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
UA107943C2 (en) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Compounds of spiropiperidines as antagonists of the orl-1 receptors |
MX343215B (es) | 2010-02-26 | 2016-10-27 | Xenon Pharmaceuticals Inc | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos. |
US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
US9963458B2 (en) | 2012-12-27 | 2018-05-08 | Purdue Pharma L.P. | Indole and indoline-type piperidine compounds and uses thereof |
WO2014102589A1 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Quinazolin-4(3h)-one-type piperidine compounds and uses thereof |
US9040533B2 (en) | 2012-12-27 | 2015-05-26 | Purdue Pharma L.P. | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators |
US9090618B2 (en) | 2012-12-27 | 2015-07-28 | Purdue Pharma L.P. | Substituted benzimidazole-type piperidine compounds and uses thereof |
WO2014102590A1 (en) | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
CA3006966A1 (en) * | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
CN106336357A (zh) * | 2016-08-29 | 2017-01-18 | 启东东岳药业有限公司 | 2‑羟甲基丙烯酸甲酯的制备方法 |
CN110143918B (zh) * | 2019-06-19 | 2020-08-04 | 青岛农业大学 | 3,4-二氢-3-(2-羟基苯甲酰)-2(1h)-喹啉酮活性骨架及合成方法和应用 |
CN113264949B (zh) * | 2021-05-31 | 2022-04-05 | 西南大学 | 一类螺苯并噁嗪哌啶α,β-不饱和酮类衍生物的设计合成与应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1087770A4 (en) | 1998-06-15 | 2001-11-14 | Merck & Co Inc | INHIBITORS OF PRENYL PROTEIN TRANSFERASE |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
DE60229736D1 (de) * | 2001-04-18 | 2008-12-18 | Euro Celtique Sa | Spiroinden- und spiroindan-verbindungen |
US20030078278A1 (en) * | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
-
2003
- 2003-01-16 CA CA002466915A patent/CA2466915A1/en not_active Abandoned
- 2003-01-16 EP EP20030700412 patent/EP1470126A1/en not_active Withdrawn
- 2003-01-16 MX MXPA04007242A patent/MXPA04007242A/es unknown
- 2003-01-16 WO PCT/IB2003/000203 patent/WO2003064425A1/en not_active Application Discontinuation
- 2003-01-16 JP JP2003564048A patent/JP2005519921A/ja not_active Withdrawn
- 2003-01-16 BR BR0307268-1A patent/BR0307268A/pt not_active IP Right Cessation
- 2003-01-23 US US10/349,760 patent/US6869960B2/en not_active Expired - Fee Related
- 2003-01-24 GT GT200300014A patent/GT200300014A/es unknown
- 2003-01-24 PE PE2003000075A patent/PE20030848A1/es not_active Application Discontinuation
- 2003-01-24 UY UY27623A patent/UY27623A1/es not_active Application Discontinuation
- 2003-01-27 TW TW092101738A patent/TW200302725A/zh unknown
- 2003-01-27 AR ARP030100227A patent/AR038235A1/es not_active Application Discontinuation
- 2003-01-28 PA PA20038564201A patent/PA8564201A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20030158219A1 (en) | 2003-08-21 |
US6869960B2 (en) | 2005-03-22 |
JP2005519921A (ja) | 2005-07-07 |
TW200302725A (en) | 2003-08-16 |
CA2466915A1 (en) | 2003-08-07 |
UY27623A1 (es) | 2003-08-29 |
MXPA04007242A (es) | 2004-10-29 |
EP1470126A1 (en) | 2004-10-27 |
PE20030848A1 (es) | 2003-10-11 |
AR038235A1 (es) | 2005-01-05 |
BR0307268A (pt) | 2004-12-14 |
PA8564201A1 (es) | 2003-12-10 |
WO2003064425A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200300014A (es) | Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 | |
GT200500185A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
GT200600030A (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
GT200300226A (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos | |
GT200600155A (es) | Compuestos utiles en terapia | |
GT200400020A (es) | Compuestos de triazol utiles en terapia | |
GT200500097A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central | |
GT200500101A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
GT200600217A (es) | Proceso para la sintesis de compuestos organicos | |
GT200600128A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
MX2009005461A (es) | N-oxidos de analogos de 4,5-epoxi-morfinano. | |
GT200600024A (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
GT200300028A (es) | Derivados iii de dihidrobenzodiacepina-2-ona | |
MX2009005462A (es) | Analogos de 7,8-saturados-4,5-epoxi-morfinano. | |
GT200300258A (es) | Activadores de ppar | |
AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
GT200300138A (es) | Moduladores del receptor de glucocorticoides | |
MX2009012561A (es) | Formas polimorficas y amorfas de esteviosida, metodos para su formulacion, y usos. | |
GT200600107A (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos | |
SI2001876T1 (sl) | 8-azabiciklo(3.2.1)oktanske spojine kot antagonisti mu-opioidnega receptorja | |
GT200600255A (es) | Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a | |
CY1108880T1 (el) | Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
GT200400226A (es) | Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos | |
GT200500051A (es) | Nuevos derivados de bencil (ideno)-lactamas | |
GT200200280A (es) | Lactamas como antagonistas de taquiquininas |